[Novel phosphate binders under development].
Controlling serum phosphorus levels in patients with chronic kidney disease is crucial. Since hyperphosphatemia is an established risk factor for not only secondary hyperparathyroidism, but also cardiovascular mortality in these patients, the adequate control of serum phosphorus is necessary. The target levels of serum phosphorus, however, are not consistently being met. To achieve better control of serum phosphorus levels, some novel phosphate binders, which do not contain calcium or metal, have been developed. In this manuscript we discuss some novel phosphate binders, which are now in clinical trials.
Mizobuchi
Masahide
M
Showa University School of Medicine, Department of Nephrology.
Sanada
Daisuke
D
Akizawa
Tadao
T
D001647:Bile Acids and Salts; D002908:Chronic Disease; D019343:Citric Acid; D002986:Clinical Trials as Topic; D015195:Drug Design; D005296:Ferrous Compounds; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy* / Q000209:etiology; D007674:Kidney Diseases / Q000150:complications; D011073:Polyamines; D012307:Risk Factors; D000069603:Sevelamer
D001647:Bile Acids and Salts; D005296:Ferrous Compounds; D011073:Polyamines; D019343:Citric Acid; C016600:ferrous citrate; D000069603:Sevelamer; C106574:cholebine